Patents by Inventor Xing Xian Yu

Xing Xian Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7825235
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: November 2, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, Brett P. Monia
  • Patent number: 7732590
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Grant
    Filed: February 24, 2005
    Date of Patent: June 8, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth W. Dobie, Xing-Xian Yu, Brett P. Monia
  • Publication number: 20090221671
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMW-PTPase in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of diabetes, insulin resistance, insulin deficiency, hypercholesterolemia, hyperglycemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, and hyperfattyacidemia. In some embodiments, the diabetes is type II diabetes by administration of antisense compounds targeted to LMW-PTPase.
    Type: Application
    Filed: May 24, 2006
    Publication date: September 3, 2009
    Inventors: Sanjay Pandey, Robert McKay, Sanjay Bhanot, Xing-Xian Yu
  • Publication number: 20090054359
    Abstract: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 26, 2009
    Inventors: Xing-Xian Yu, Sanjay Bhanot, Brett P. Monia
  • Publication number: 20080255030
    Abstract: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.
    Type: Application
    Filed: August 6, 2007
    Publication date: October 16, 2008
    Inventors: Xing-Xian Yu, Sanjay Bhanot
  • Patent number: 7141421
    Abstract: The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: November 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Sean H. Adams, Xing Xian Yu
  • Publication number: 20050272680
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Application
    Filed: February 24, 2005
    Publication date: December 8, 2005
    Inventors: Sanjay Bhanot, Kenneth Dobie, Xing-Xian Yu, Brett Monia
  • Publication number: 20050043524
    Abstract: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 2 are provided.
    Type: Application
    Filed: August 18, 2003
    Publication date: February 24, 2005
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Kenneth Dobie, Xing-Xian Yu
  • Publication number: 20040146908
    Abstract: The present invention is directed to novel polypeptides belonging to the fibroblast growth factor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating obesity are provided.
    Type: Application
    Filed: November 12, 2003
    Publication date: July 29, 2004
    Applicant: Genentech, Inc.
    Inventors: Sean Adams, Audrey Goddard, Austin L. Gurney, Timothy A. Stewart, Elizabeth Tomlinson, Xing Xian Yu
  • Publication number: 20020155543
    Abstract: The present invention is directed to novel polypeptides belonging to the fibroblast growth factor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Furthermore, methods of treating obesity are provided.
    Type: Application
    Filed: August 7, 2001
    Publication date: October 24, 2002
    Applicant: GENENTECH, INC.
    Inventors: Sean Adams, Audrey Goddard, Austin L. Gurney, Timothy A. Stewart, Elizabeth Tomlinson, Xing Xian Yu
  • Publication number: 20020119137
    Abstract: An isolated polypeptide comprising an amino acid sequence having at least 80% sequence identity to the sequence SEQ ID NO:1, polynucleotides encoding these peptides, and antibodies to the polypeptides are useful in treating metabolic disorders or disorders associated with changes in adipose tissue physiological function or mass.
    Type: Application
    Filed: June 22, 2001
    Publication date: August 29, 2002
    Inventors: Sean H. Adams, David Lewin, Xing Xian Yu
  • Publication number: 20020103150
    Abstract: The present invention is directed to compositions and methods related to the use of human OGC as an uncoupling protein.
    Type: Application
    Filed: June 22, 2001
    Publication date: August 1, 2002
    Inventors: Sean H. Adams, Xing Xian Yu